Vázquez-Ortega L, Fernández-Carreño A, Cantellano-Orozco M, Camarena-Reynoso H, Hernández-Castellanos V, Shuck-Bello C, Leos-Acosta C, Andrade-Platas D, Morales-Montor G, Pacheco-Gablher C, Calderón-Ferro F

Language: Spanish
References: 13
Page: 203-206
PDF size: 135.40 Kb.

ABSTRACT

Background: Prostate antigen density defined as the relation of the antigen value with total prostate volume is argued to be one of the diagnostic elements for prostate cancer in patients presenting with negative rectal examination and prostate antigen ‹10 ng/ml. It has been shown that this density can help predict biopsy positivity, decrease the number of unnecessary biopsies and predict the aggressiveness of the disease.
Materials and methods: A retrospective, crosssectional study was carried out which took into account all patients who had had prostate biopsies within the last 5 years at our hospital and studies determining initial prostate antigen, transrectal ultrasound measuring prostate volume and antigen density, transitional zone volume and density, histopathological results and Gleason score in cases of adenocarcinoma, number of positive fragments and their percentages. Statistical analysis was carried out to evaluate sensitivity and specificity of different cut–off point values.
Results: From a total of 747 biopsies, 260 patients met with all established inclusion criteria. Mean age was 68 years with a range from 43 to 88 years. Mean prostate antigen was 23.26 with a range from 0.6 to 623 ng/dL. Prostate density varied from 0.01 to 5.08 ng/ml. When cut –off point value was 0.17 ng/mL/cc there was 77% sensitivity, a 60% specificity and 87% negative predictive value.
Conclusions: A cut-off point of 0.17 ng/mL/cc is helpful in adequately predicting the absence of cancer in prostate biopsies.

REFERENCES

1. James B, Armenakas N, Fracchia J. Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to10 ng/mL. J Urol 2007;177:1741-1744.

2. Spurgeon S, Hsieh Y, Rivadinera A, Garzotto M. Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. J Urol 2006;175:918-922.

3. Gjengsto P, Paus E, Halvorsen J, Hoisaeter PA. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. J Urol 2005;173:425-428.

4. Warlick C, Trock B, Landis P. Delay versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98(5):355-7.

5. Kundu S, Rohel K, Catalona W. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007;177:505-509.

6. Morote. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/mL. J Urol 1994;158:502.

7. Lam J, Cheung K, Benson M, Goluboff E. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. J Urol 2003;170:451-456.

8. Bazinet M. Prospective evaluation of prostate-specific density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.

9. Beduschi MC. Prostate-specific antigen density. Urol Clin N Am 1997;24:323.

10. Garza M. Importancia de la densidad del APE en el diagnóstico de cáncer de próstata. Rev Mex Urol 2005;65(6) 427-430.

11. Ohigashi T, Kanao K, Murais M. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy. J Urol 2005;173:1541-1545.